Metrogyl

Metronidazole, the active ingredient in Metrogyl, is a nitroimidazole antibiotic presented as a sterile solution for intravenous use. It treats anaerobic bacterial infections and certain protozoal infections in adults and children as prescribed.

GNH USA supplies Metrogyl as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Metrogyl is a nitroimidazole antibiotic used to manage infections caused by anaerobic bacteria and specific protozoa.

- Anaerobic bacterial infections: effective against mixed anaerobic infections, reducing bacterial load. - Clostridioides difficile infection: helps resolve toxin‑mediated colitis. - Bacterial vaginosis: restores normal vaginal flora by targeting anaerobic organisms. - Pelvic inflammatory disease: treats anaerobic components of upper genital tract infection. - Amoebiasis: eliminates Entamoeba histolytica trophozoites in intestinal and extra‑intestinal disease.

Metrogyl may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Metallic taste - Headache - Diarrhea - Abdominal pain - Dizziness

Serious or Rare Side Effects: - Anaphylaxis (severe allergic reaction) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Seizures - Hepatotoxicity (liver injury) - Neutropenia (low white blood cell count) - Peripheral neuropathy (nerve damage).

Before prescribing Metrogyl, clinicians should consider several safety measures.

- Assess renal function: adjust dose in severe impairment. - Monitor hepatic function: use cautiously in liver disease. - Avoid alcohol: risk of disulfiram‑like reaction. - Use contraception: potential embryotoxic effects. - Store at ambient temperature: keep in original container, protect from light and moisture.

Metrogyl can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Alcohol: may cause severe disulfiram‑like reaction. - Warfarin: increased anticoagulant effect, risk of bleeding. - Lithium: heightened lithium toxicity.

Moderate Interactions (Monitor Closely): - Cimetidine: may raise metronidazole plasma levels. - Phenobarbital: may reduce metronidazole effectiveness. - Phenytoin: may lower metronidazole concentrations.